8 stories mentioning HKG:2493
Every FINWIRES story that references HKG:2493, newest first.
Mabwell (Shanghai) Bioscience (HKG:2493, SHA:688062) has received regulatory approval in China and the U.S. to begin clinical trials of 9MW5211, which targets inflammatory bowel disease (IBD), according to a Thursday filing with the Hong Kong bourse.The company's Hong Kong shares fell over 1% in morning trade Friday.
Mabwell (Shanghai) Bioscience (HKG:2493, SHA:688062) said Chinese regulators expanded denosumab's approval to include new indications, according to a Wednesday filing with the Hong Kong bourse.The firm's Hong Kong shares gained nearly 4% in morning trade Thursday.Denosumab, also known as maiweijian and 9MW0321, will now be available to treat bone metastases from solid tumors and to delay or reduce the risk of skeletal-related events in patients with multiple myeloma.The medicine, a biosimilar version of Xgeva, was previously approved in China to treat giant cell tumor of the bone.
Hong Kong stocks extended losses on Tuesday as elevated oil prices and persistent tensions in the Middle East kept inflation concerns in focus.The Hang Seng Index fell 245.87 points, or 1.0%, to close at 25,679.78, while the Hang Seng China Enterprises Index lost 111.51 points, or 1.3%, to 8,644.81.An U.S. official said President Donald Trump was dissatisfied with Iran's latest proposal to resolve the two-month conflict.The proposal would defer discussion of Iran's nuclear program until the conflict ends and shipping disputes in the Gulf are addressed, according to a Reuters report.The impasse has left the conflict at a standstill, with flows through the Strait of Hormuz still largely disrupted, keeping oil prices above $100 a barrel.Meanwhile, the U.S. Federal Reserve is widely expected to keep interest rates unchanged at the conclusion of its two-day meeting on Wednesday.In corporate news, two firms made their debut on the Hong Kong bourse.Shanghai Xizhi Technology (HKG:1879) closed nearly 389% higher at HK$895 compared with the offer price of HK$183.20.Mabwell (Shanghai) Bioscience (HKG:2493, SHA:688062) gained nearly 1% to close at HK$27.80, versus its offer price of HK$27.64.
Mabwell (Shanghai) Bioscience's (HKG:2493, SHA:688062) shares opened 2.4% above their initial public offering price in a steady Hong Kong debut on Tuesday morning.The China-based pharmaceutical firm opened at HK$28.30 per share, compared with the offer price of HK$27.64.
Mabwell (Shanghai) Bioscience (HKG:2493, SHA:688062) raised HK$1.19 billion in net proceeds from its initial public offering in Hong Kong.The final offer price was set at HK$27.64 per H-share, according to a Monday after-market filing with the Hong Kong Stock Exchange.The China-based pharmaceutical firm offered 47.1 million H-shares in the global offering.The Hong Kong public offer was 481.71 times subscribed, with a final allocation of 4.7 million shares, representing 10% of the total offering.The international offering was 3.46 times subscribed, with a final allocation of 42.4 million shares, or 90% of the total offering.Cornerstone investors, including Junshi Hong Kong, Sanjin International, Guohui (HK) Holdings, WuXi Biologics HealthCare Venture, and Splendid Zhonghe, were allotted a combined 15 million shares, according to the filing.Mabwell is scheduled to debut on the Hong Kong bourse on Tuesday, April 28.
Mabwell (Shanghai) Bioscience (HKG:2493, SHA:688062) has set its Hong Kong listing offer price at HK$27.64 per share, according to an April 24 bourse filing.The China-based pharmaceutical firm expects to announce allocation results on Monday.Shares are scheduled to begin trading on Tuesday, with board lots of 200 shares.
Hong Kong stocks finished higher Monday as investors remained cautiously optimistic over the prospect of a diplomatic breakthrough between Iran and the U.S.The Hang Seng Index rose by 200.74 points, or roughly 0.8%, to end at 26,361.07, while the Hang Seng China Enterprises Index increased by 54.04 points, or around 0.6%, to close at 8,899.06.Tensions brewed after a US Navy destroyer, USS Spruance, intercepted an Iranian-flagged cargo vessel called Touska near the Strait of Hormuz and Iran issued a warning to the US.Despite an announcement from Iran that it had again closed the strait, 20 ships had transited from the narrow passage on Saturday, Reuters reported, citing Kpler data.The ongoing conflict in the Middle East is helping Hong Kong reassert itself as a haven in global finance, thanks to its geographical location and support from China's economic strength, the South China Morning Post said in a report.According to the paper, banks had turned to the city to protect their business, while global investors had inquired about adding allocations of mainland Chinese assets to their portfolio.In corporate news, two mainland Chinese firms filed to go public in Hong Kong.Shanghai Xizhi Technology (HKG:1879) is looking to raise up to HK$2.53 billion via the sale of 13.8 million shares at a maximum price of HK$183.20 each. The optoelectronic computing company will use the proceeds to advance research and development.Meanwhile, Mabwell (Shanghai) Bioscience (HKG:2493, SHA:688062) is seeking about HK$1.45 billion via the sale of 47.1 million H-shares for up to HK$30.71 per share.Net proceeds will be used primarily to advance clinical trials of the pharmaceutical company's core product, 9MW2821, across multiple indications, including urothelial carcinoma, triple-negative breast cancer, and cervical cancer.
Mabwell (Shanghai) Bioscience (HKG:2493, SHA:688062) launched its Hong Kong initial public offering on Monday, seeking to raise up to about HK$1.45 billion from the deal.The China-based pharmaceutical company is offering 47.1 million H-shares at an indicative price range of HK$27.64 to HK$30.71 per share, according to a Hong Kong bourse filing.The offering comprises 4.7 million shares for Hong Kong investors and 42.4 million shares for international investors, subject to reallocation.The offer price is expected to be determined by April 24, with allocation results due by April 27, ahead of the company's planned trading debut on April 28.Net proceeds will be used primarily to advance clinical trials of the company's core product, 9MW2821, across multiple indications, including urothelial carcinoma, triple-negative breast cancer, and cervical cancer.The funds will also support the development of other pipeline products, commercialization efforts, and working capital and general corporate purposes.CITIC Securities (Hong Kong) and Haitong International Capital are acting as joint sponsors.CLSA, Haitong International Securities, China Industrial Securities International Capital, CMB International Capital, CCB International Capital, Guosen Securities (HK) Brokerage, and Futu Securities International (Hong Kong) are acting as joint bookrunners and joint lead managers, while ABCI Capital is also a joint bookrunner.